{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77"}],"title":"Evaluable for toxicities"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Not evaluable for toxicities, participant was not treated"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"Toxicities will be assessed via the NCI toxicity criteria (CTC 3.0).","groups":[{"description":"This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.\n\nDNA analysis\n\nimmunologic technique\n\npharmacological study\n\niodine I 131 monoclonal antibody 3F8\n\n131I-3F8: Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.","id":"OG000","title":"131I-3F8"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants Evaluable for Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}